NEW YORK – Roche announced on Monday that it has entered an agreement with Ibex Medical Analytics to jointly develop an embedded image analysis workflow for pathologists.
Under the agreement, users of Roche's Navify Digital Pathology software — the cloud version of the firm's uPath software — will be able to access Ibex's artificial intelligence algorithms and tools, including its algorithms that analyze prostate and breast biopsies.
Tel Aviv-Yafo, Israel-based Ibex's Galen platform has received breakthrough device designation from the US Food and Drug Administration and got CE marking for breast and prostate cancer detection last year.
"Digital pathology provides the capability to introduce new, innovative ways for laboratories to improve quality and efficiency of cancer diagnosis," Ibex cofounder and CEO Joseph Mossel said in a statement. "Together with Roche, we look forward to transforming pathology by delivering powerful AI-based tools to the fingertips of pathologists."
Last week, Roche announced a similar agreement with PathAI. Both deals fall under Roche's Digital Pathology Open Environment program, which allows pathologists to access third-party AI-based technology along with Roche's own menu of AI-based image analysis tools.